REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.89
+1.16%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 761.92x
- P/S forward
- 20.08x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 9.67x
- Price / sales
- —
- Price / cash flow
- -8.07x
Enterprise value
- Enterprise value
- $1.8B
- EV / sales
- —
- EV / EBITDA
- -6.95x
- EV / EBIT
- -6.67x
- Market cap
- $2.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Sep 1, 2026